Clinical and immunological correlates of long term survival in glioblastoma

Bartosz Czapski[1,2,3], Szymon Baluszek[1], Christel Herold-Mende[4], Bozena Kaminska[1,2]

[1]Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology
 of the Polish Academy of Sciences, Warsaw, Poland
[2]Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland
[3]Department of Neurosurgery, Mazovian Bródnowski Hosptial, Warsaw, Poland
[4]Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany

Glioblastoma (GBM) is the most common and most aggressive type of primary brain tumour in adults. It represents 54% of all gliomas and 16% of all brain tumours (Ostrom et al. 2016). Despite surgery and treatment with radiotherapy plus an oral alkylating agent, temozolomide (TMZ), tumours invariably recur, and the patient survival is an average of ~14–16 months. In this review we summarise the current understanding of multiple factors that may affect survival of patients with GBMs. In particular, we discuss recent advancements in surgery and detection of genomic-based markers with prognostic values, such as *IDH1/2* mutations, *MGMT* gene promoter methylation, and *TERT* gene promoter alterations. We address the issue of tumour heterogeneity and evolution that may result in different parts of the same tumour exhibiting different GBM subtypes and in subtype switching, which may restrict the usefulness of the expression-based classification as a prognostic marker before relapse. The determinants of long-term survival in patients with *IDH1/2*wt GBM, beyond *MGMT* promoter methylation, remain to be identified, and even the absence of both *IDH1/2* mutations and *MGMT* promoter methylation does not preclude long-term survival. These findings suggest that host-derived factors, such as immune system responsiveness may contribute to long-term survival in such patients. We report the results of high-throughput approaches, suggesting links between long-term survival and enhanced immune-related gene expression. The further search for new gene candidates, promoter methylation status, and specific features of host immunity should provide prognostic biomarkers for the evaluation of survival of IDH1 wild-type/non-G-CIMP GBMs.

Key words: glioblastoma, immunology, long-term survival, IDH, MGMT, TERT, evolution surgery.

Introduction

Glioblastoma (GBM) is the most common and most aggressive type of primary brain tumour in adults. It represents 54% of all gliomas and 16% of all brain tumours [1]. Therapeutic options are narrow and consist of surgery and treatment with radiotherapy plus an oral alkylating agent, temozolomide (TMZ). Despite the benefits from radiotherapy/TMZ treatment, the patient survival is an average of ~14–16 months and tumours invariably recur, leading to a fatal outcome.

Despite many efforts, the prognosis for this type of cancer is still very poor and practically unchanged since 2000, when temozolomide [2, 3] was introduced into clinical practice. Despite many efforts, in patients undergoing aggressive treatments, progression-free survival (PFS) is 7–8 months, median survival is 14–16 months, and 5-year overall survival (OS) is 9.8% [4, 5]. Despite the poor prognosis, some patients manage to survive for a relatively long time, which is of interest to both clinicians and researchers. In the case of glioblastoma, long-term survivors are often defined as patients who have survived for more than 2 years after diagnosis [6] and a small fraction of GBM patients (9.8%) survive for exceptionally long periods. Studying the clinical and molecular characteristics of these rare instances of long-term survival (LTS) among GBM patients may provide insights into both GBM pathobiology and help to identify potential new prognostic biomarkers.

Surgery and new surgical approaches

Aggressive infiltration of the brain parenchyma by glioblastoma cells makes tumour resection a real challenge for physicians and, at present, prevents complete cure. Surgical treatment, albeit of great importance, is not sufficient and fully effective due to the fuzzy boundary between tumour and healthy tissue, and patient safety during the surgery. However, among other positive prognostic factors, such as age at diagnosis, the patient's wellbeing, tumour histologic type and its genetic profile, surgical treatment and its extent is the only one which can be directly influenced. Complete macroscopic tumour removal (gross total resection, GTR) in comparison to subtotal removal or biopsies statistically prolongs PFS as well as OS in both low-grade (> 120 months with GTR vs. 56 months if STR or 23 if no treatment was undertaken) [7] and malignant gliomas, including gliosarcoma, where survival after GTR is increased up to 20 months (8.8 months with no GTR) [8–10]. The subtotal resection unfortunately has a comparable impact on the OS as the execution of the brain biopsy alone and results in poor prognosis [11]. In the case of sub-total resection of the tumour during primary surgery

or its relapse, extension of the resection during secondary operation is associated with an increase in OS to a level comparable to the time when GTR was achieved at the time of first surgery (18.5 months and 9.7 months) [12, 13]. Typically, GBM presents as a solitary lesion. Nonetheless, multiple synchronous lesions are present in 0.5 to 20% of cases. It has been shown, that surgery targeting all lesions amenable for resection gave similar outcomes to matched cases of unifocal GMB [14].

According to the generally accepted definition, total tumour removal is achieved when neuroimaging studies confirm complete removal of contrast-enhancing regions or hyperintensive T2/FLAIR regions [15]. In order to maximise surgical resection, intraoperative MR imaging, intraoperative ultrasonography and intraoperative tumour staining can be used to maximize surgical resection [16]. Combined with the awake surgery and eloquent brain mapping the complete glioma resection is up to 96% [17]. Without the use of advanced imaging techniques, total tumour removal was achieved on average only in 68% of patients [18]. A randomised, controlled, multicentre trial has shown that fluorescence-guided resection with use of 5-ALA was superior to white light resection both in terms of GTR (65 vs. 35%) and 6-month PFS (42 vs. 21%) [19]. There is a growing number of other fluorescent agents, including ones targeting EGFR, PPARP1, or integrins, which could be utilised for research or clinical purposes in the future [20]. Retrospective analysis of resected tumours has shown that gliomas harbouring *IDH* mutations are more amenable for surgical treatment, thus having a better prognosis after maximal surgical excision [21].

Genomic correlates of better survival and response to chemotheraphy

Chemotherapy of brain tumours has limited options due to poor penetration of drugs through the blood-brain barrier. High cellular and genomic heterogeneity of glioblastoma is an additional obstacle that significantly limits therapeutic options [22]. Despite the failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, EGFR remains a dominant molecular alteration in GBM subtypes and represents a promising target, with various targeting drugs, including vaccines, antibody drug conjugates, and chimeric antigen receptor (CAR) T cells. Immune therapies under investigation include checkpoint inhibitors, vaccines against tumour-associated antigens and tumour-specific antigens, activated dendritic cells, heat shock protein-tumour conjugates, and CAR T cells [23]. So far, these approaches have failed to result in the successful application of targeted therapies, and chemotherapy with DNA damaging drugs remains the main option. Standard treatment is maximal tumour resection followed by 6-week chemoradiotherapy (60Gy + temozolomide 75 mg/m^2). Hydrochlorothiazide is then used for a minimum of 6 months (150-200 mg/m^2 for 5 days every 28 days) [24].

Methylation of the *MGMT* gene promoter

Promoter methylation of the O(6)-methylguanine-DNA-methyltransferase (MGMT) gene has been con-

sidered a prognostic marker and has become more important in the treatment of glioblastoma. MGMT is a DNA repair protein that removes alkyl groups from the guanine O6 position. When *MGMT* promoter is methylated, the protein is not present and cells tend to be more sensitive to alterations induced by alkylation, which leads to cell death by apoptosis [25]. Response to treatment with alkylating agents (temozolomide or carmustine for glioblastoma) is dependent on the methylation state of the *MGMT* gene promoter [26]. This translates into a clinical effect – survival of patients with methylated *MGMT* promoter treated with TMZ was significantly higher (21.7 months) compared with patients with non-methylated *MGMT* (15.3 months) [27]. Interestingly, *MGMT* promoter methylation was statistically significantly related to survival over 3 years, but was no longer significant in patients who survived 5 years or more [28]. Surprisingly, *MGMT* gene methylation is prognostic but not predictive of response to TMZ chemotherapy in anaplastic glioma [29]. These results can be explained either by the fact that *MGMT* methylation is associated with an otherwise positive prognostic factor, *IDH1/2* mutation in the anaplastic gliomas. Moreover, loss of chromosome 10, occurring in the majority of GBM cases, leads to an absolute lack of MGMT function.

IDH1/2 mutations

Isocitrate dehydrogenase (IDH)1/2 mutations are found in nearly 70% of low-grade gliomas [30] and around 12% of glioblastomas [31]. Mutations in *IDH1/2* are associated with an excessive methylation of the genome which results in glioma-specific CpG island methylator phenotype (G-CIMP) [32]. *IDH* mutations are linked to cellular metabolic changes [32, 33] and production of 2-hydroxyglutarate, an oncometabolite, which when accumulated leads to inhibition of DNA demethylase TET2 and altered DNA methylation [34], inhibition of proline hydroxylases, induction of ROS (reactive oxygen species) by decreasing NADPH level in the cell [35], aberrant chromatin conformation due to enhanced histone methylation [36, 37] and induction of HIF-1 mediated angiogenesis [38]. So far, attempts at predicting tumour *IDH1/2* status, based on detection of 2-hydroxyglutarate (2-HG) in serum, have failed. 2-HG concentration in serum from patients with gliomas does not correlate with *IDH1/2* mutation status or tumour size [39]. Irrespectively, magnetic resonance spectroscopy peak at 2.25 ppm was shown to strongly correlate with *IDH1/2* mutation and 2-HG concentration in resected specimens [40]. *IDH* mutations are commonly associated with *MGMT* promoter methylation as a part of the specific methylation phenotype (79% of G-CIMP vs. 46% for non-G-CIMP) [41]. *IDH1/2* mutation demarcates oligodendroglioma, astrocytoma, and secondary GBM from primary GBM and lower-grade gliomas with biology similar to GBM. The effect on long-term survival was directly related to the presence of mutations in *IDH1/2* genes [42]. *IDH1/2* mutated tumours were more frequently unilobular lesions. In contrast, *IDHwt* lesions were more prone to occur in the brainstem and in multiple lobes and were significantly more often found in a location bearing high surgical risk [43]. Despite the im-

portant role in glioblastoma pathogenesis, *IDH* mutations alone are hardly associated with long-term GBM survival [44, 45]. Moreover, a recent study shows that there was no survival benefit for *IDH1*-mut GBMs when controlled for location: 25.2 months overall survival for *IDH1*-mut patients and 23.6 for *IDH1*-wild type patients [46, 47]. On the other hand, *IDH* mutations when paired with *MGMT* promoter methylation status are statistically significant prognostic factors for long-term survival and response to treatment of GBM patients [47–49].

Global DNA methylation profiling of tumours isolated from long-term (> 36 months) and short-term (6–10 months) surviving GBM patients (*IDH1* wild-type/non-G-CIMP) revealed hypermethylation of multiple CpGs mapping to the promoter region of LOC283731 which correlated with improved patient outcome. The prediction was most pronounced in younger GBM patients (< 60 years old) [50]. In a recent study of DNA methylation profiles, a set of CpG loci differentially hypermethylated between short-term and long-term GBM cases was identified, including genomic regions coding for members of the homeobox gene family (HOXD8, HOXD13 and HOXC4), the transcription factors NR2F2 and TFAP2A, and DICKKOPF2, a negative regulator of the WNT/β-catenin signalling pathway [51].

TERT promoter mutations

Recent findings on cancer genetics have found that over 85% of tumours show up-regulated telomerase complex which may lead to cancer cell immortality by preventing telomeres shortening and enabling infinite cell proliferation [52–54]. Mutations in the promoter region of *TERT* gene lead to up-regulation of its mRNA and protein resulting in telomere elongation in gliomas [55]. Highest frequency of hotspot mutations of the *TERT* gene promoter in gliomas are found in gliosarcomas (81%), oligodendrogliomas (78%) and primary glioblastomas (83–54%) [56, 57]. Gliomas harbouring *TERT* promoter mutations have worse prognosis in comparison to *TERT* wild-type gliomas (27 vs. 14 months), excluding *TERT-IDH* double mutated subgroup which seems to have a very good prognosis reaching overall survival even higher than 17 years [52, 58, 59]. The poor survival of *TERT* promoter-mutated gliomas was associated with higher radiotherapy resistance [60]. The prognostic value of *TERT* promoter mutation was absent in completely resected GBMs treated with temozolomide leading to assumptions that *TERT*-mut GBMs are a subgroup of tumours which need to be treated as aggressively as possible [61]. A meta-analysis of nine studies with adjusted outcomes showed that *TERT* promoter mutations were associated with a worse prognosis of patients with gliomas [62].

Tumour evolution under therapy

Recent integrative studies of molecular data and clinical variables in recurrent GBMs showed GBM evolution, heterogeneity and specific alterations associated with treatment. Whole-genome and whole-exome sequencing of multiple regions from primary and paired recurrent GBMs revealed both the occurrence of the same mutations in both samples (suggestive of clonal evaluation) and divergent tumours that share few genetic alterations with the primary tumour. The study showed TMZ induced hypermutation [63]. A recent study combining genomic and transcriptomic data from 114 GBM patients shows that despite 45% of mutations being shared by diagnostic and relapse samples, the dominant clone at diagnosis was generally not a linear ancestor of the dominant clone at relapse. In particular, 11% of patients exhibited replacement of one mutated gene (at diagnosis) with a differently mutated version of the same gene (at relapse). This mutational switching was enriched ~200-fold in genes implicated in GBM, such as *EGFR*, *TP53*, and *PDGFRA*. Moreover, two-thirds of patients with primary GBM displayed different transcriptional subtypes at diagnosis and relapse [64]. This observation of subtype switching, together with recent findings that different parts of the same tumour can exhibit different GBM subtypes [65] may restrict the usefulness of the expression-based classification as a prognostic marker before relapse.

Immunological correlates of long term survival in glioblastoma

It has been shown that *IDH1/2* wild-type GBM patients with long-term survival exhibit no specific markers distinguishing them from *IDH1/2* wild-type GBM patients with poor outcome. Long-term surviving patients with and without *IDH1/2* mutations, share an increased prevalence of *MGMT* promoter methylation. The determinants of long-term survival in patients with *IDH1/2*wt GBM, beyond *MGMT* promoter methylation, remain to be identified, and even the absence of both *IDH1/2* mutations and *MGMT* promoter methylation does not preclude long-term survival [45]. These findings suggest that host-derived factors, such as immune system responsiveness may contribute to long-term survival in such patients. First high-throughput approaches have suggested links between long term survival and decreased retinoic acid signalling [66] or enhanced immune-related gene expression [67].

Gene expression microarray profiling of high grade astrocytomas from long-term survivors revealed the increased expression of immune function-related genes (such as *CD3D, CD3E, CD3G, CD8B, TRAC, TRAT1, VAV1,* and *ZAP70* expressed by T cells) was associated with longer survival. Notably, the T cell signature was predominant within this prognostic immune gene set. This association of immune function and cell-specific genes with survival was confirmed independently in a larger public GBM gene expression microarray data set [67]. Transcriptomic studies and pathway analysis of differentially regulated genes implicated tumour-promoting, microglia-driven inflammatory processes in short-term GBM survivors. Transcriptomic analyses and multicolor immunofluorescence staining have provided further evidence for higher numbers of pro-tumourigenic, M2-like microglia in short-term surviving patients with GBMs [68]. This is consistent with the pro-tumourigenic role of glioma infiltrating microglia/macrophages (GAMs) and correlation between numbers of

activated GAMs and glioma grade [69, 70]. These findings provide important insights into the association of innate immune response and survival in *IDHwt* GBMs.

The authors declare no conflict of interest.

References

1. Ostrom Q, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumours Diagnosed in the United States in 2009–2013. Neuro-Oncology 2016; 18 (suppl_5): v1-v75.
2. FDA Approved Drug Products. Drugs@FDA: FDA Approved Drug Products. [online] Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021029 [Accessed 31 May 2017].
3. Walid M. Prognostic Factors for Long-Term Survival after Glioblastoma. Perm J 2008; 12: 45-8.
4. Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
5. Scott J, Rewcastle N, Brasher P, Fulton D, MacKinnon J, Hamilton M, Cairncross J, Forsyth, P. Which glioblastoma multiforme patient will become a long term survivor? A population based study. Ann Neurology 1999; 46: 183-8.
6. Bruce J, Kennedy B, Engelhard H, Shepard R. Glioblastoma Multiforme: Practice Essentials, Background, Pathophysiology. [online] Emedicine.medscape.com. Available at: http://emedicine.medscape.com/article/283252-overview 2017 [Accessed 31 May 2017].
7. Schupper A, Hirshman B, Carroll K, Ali M, Carter B, Chen C. Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis. World Neurosurg 2017; 103: 741-747.
8. Frandsen J, Orton A, Jensen R, Colman H, Cohen A, Tward J, Shrieve D, Suneja G. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 2017; 1-6; doi: 10.3171/2016.12.JNS162291.
9. Brown T, Brennan M, Li M, et al. Association of the Extent of Resection With Survival in Glioblastoma. JAMA Oncol 2016; 2: 1460-9.
10. Almeida J, Chaichana K, Rincon-Torroella J, Quinones-Hinojosa A. The Value of Extent of Resection of Glioblastomas: Clinical Evidence and Current Approach. Curr Neurol Neurosci Rep 2014; 15: 517.
11. Trifiletti D, Alonso C, Grover S, Fadul C, Sheehan J, Showalter T. Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database. World Neurosurg 2017; 103: 330-40.
12. 12. Montemurro N, Perrini P, Blanco M, Vannozzi R. Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin Neurol Neurosurg 2016; 142: 60-4.
13. Bloch O, Han S, Cha S, Sun M, Aghi M, McDermott M, Berger M, Parsa A. Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg 2012; 117: 1032-8.
14. Hassaneen W, Levine N, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. J Neurosurg 2011; 114: 576-84.
15. D'Amico R, Englander Z, Canoll P, Bruce J. Extent of Resection in Glioma–A Review of the Cutting Edge. World Neurosurg 2017; 103: 538-49.
16. Catapano G, Sgulò F, Seneca V, Lepore G, Columbano L, di Nuzzo G. Fluorescein-guided Surgery for High Grade Glioma Resection: an Intraoperative "Contrast-enhancer". World Neurosurg 2017; 104: 239-247.
17. Huberfeld G, Trébuchon A, Capelle L, Badier J, Chen S, Lefaucheur J, Gavaret M. Preoperative and intraoperative neurophysiological investigations for surgical resections in functional areas. Neurochirurgie 2017; 63: 142-9.
18. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011; 12: 997-1003.
19. Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
20. Craig S, Wright J, Sloan A, Brady-Kalnay S. Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review. World Neurosurg 2016; 90: 154-63.
21. Beiko J, Suki D, Hess K, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncol 2013; 16: 81-91.
22. Weller M, Cloughesy T, Perry J, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet?. Neuro-Oncol 2012; 15: 4-27.
23. Touat M, Idbaih A, Sanson M, Ligon K. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 2017; 28: 1457-72.
24. Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New Engl J Med 2005; 352: 987-96.
25. Ochs K, Kaina B. Apoptosis Induced by DNA Damage O 6-Methylguanine Is Bcl-2 and Caspase-9/3 Regulated and Fas/Caspase-8 Independent. Cancer Research 2000; 60: 5815-24.
26. Esteller M, Garcia-Foncillas J, Andion E, Goodman S, Hidalgo O, Vanaclocha V, Baylin S, Herman J. Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents. New Engl J Med 2000; 343: 1350-4.
27. Hegi M, Diserens A, Gorlia T, et al. MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma. New Engl J Med 2005; 352: 997-1003.
28. Nakagawa Y, Sasaki H, Ohara K, Ezaki T, Toda M, Ohira T, Kawase T, Yoshida K. (2017). Clinical and molecular prognostic factors for long-term survival of the patients with glioblastomas in a single institutional consecutive cohort. World Neurosurg 2017; 106: 165-73.
29. van den Bent M, Dubbink H, Sanson M, et al. MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumours: A Report From EORTC Brain Tumour Group Study 26951. J Clin Oncol 2009; 27: 5881-6.
30. Yan H, Parsons D, Jin G, et al. IDH1andIDH2Mutations in Gliomas. New Engl J Med 2009; 360: 765-73.
31. Parsons D, Jones S, Zhang X, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 2008; 321: 1807-12.
32. Waitkus M, Diplas B, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncol 2015; 18: 16-26.
33. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumour Pathol 2012; 29: 131-9.
34. Dang L, White D, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
35. Lee S, Koh H, Park D, Song B, Huh T, Park J. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radical Biol Med 2002; 32: 1185-96.
36. Lu C, Ward P, Kapoor G, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-8.
37. Chowdhury R, Yeoh K, Tian Y, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO reports 2011; 12: 463-9.
38. Zhao S, Lin Y, Xu W, et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1. Science 2009; 324: 261-5.
39. Capper D, Simon M, Langhans C, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumour size. Int J Cancer 2011; 131: 766-8.
40. Choi C, Ganji S, DeBerardinis R, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Med 2012; 18: 624-9.
41. Brennan C, Verhaak R, McKenna A, et al. The Somatic Genomic Landscape of Glioblastoma. Cell 2013; 155: 462-77.
42. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81: 1515-22.

43. Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y, Han H, Zhang X. Isocitrate dehydrogenase mutation is associated with tumour location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncology Letters 2014; 7: 1895-902.

44. Amelot A, De Cremoux P, Quillien, V, et al. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLOS One 2015; 10: p.e0130596.

45. Hartmann C, Hentschel B, Simon M, et al. Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. Clin Cancer Res 2013; 19: 5146-57.

46. Paldor I, Drummond K, Kaye A. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumour location: A case-control study. J Clin Neurosci 2016; 34: 117-20.

47. Millward C, Brodbelt A, Haylock B, et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochirurgica 2016; 158: 1943-53.

48. Gerber N, Goenka A, Turcan S, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology 2014; 16: 1186-95.

49. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncology 2013; 15: 469-79.

50. Mock A, Geisenberger C, Orlik C, et al. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int J Cancer 2016; 139: 424-32.

51. Shinawi T, Hill V, Krex D, et al. DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics 2013; 8: 149-56.

52. Yuan Y, Qi C, Maling G, et al. TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci 2016; 26: 57-62.

53. Walsh K, Wiencke J, Lachance D, Wiemels J, Molinaro A, Eckel-Passow J, Jenkins R, Wrensch M. Telomere maintenance and the etiology of adult glioma. Neuro-Oncol 2015; 17: 1445-52.

54. Xu L, Li S, Stohr B. The Role of Telomere Biology in Cancer. Annu Rev Pathol 2013; 8: 49-78.

55. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica 2013; 126: 267-76.

56. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumours of the nervous system. Acta Neuropathologica 2013; 126: 907-15.

57. Killela P, Reitman Z, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumours derived from cells with low rates of self-renewal. Proc Nat Acad Sci U S A 2013; 110: 6021-6.

58. Labussière M, Di Stefano A, Gleize V, et al. (2014). TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 2014; 111: 2024-32.

59. Killela P, Pirozzi C, Healy P, et al. Mutations inIDH1,IDH2, and in theTERTpromoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014; 5: 1515-25.

60. Gao K, Li G, Qu Y, Wang M, Cui B, Ji M, Shi B, Hou P. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. Oncotarget 2016; 7: 8712-25.

61. Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro-Oncol 2014; 17: 45-52.

62. Wang X, Li X, Xu F, Zhang Y, Liu H, Tao Y. Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis. Molecular Neurobiology 2015; 53: 2726-32.

63. Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nature Genetics 2016; 48: 768-76.

64. Kim H, Zheng S, Amini S, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumour evolution. Genome Res 2015; 25: 316-27.

65. Patel A, Tirosh I, Trombetta J, et al. Single-cell RNA-seq highlights intratumoural heterogeneity in primary glioblastoma. Science 2014; 344: 1396-401.

66. Barbus S, Tews B, Karra, D, et al. Differential Retinoic Acid Signaling in Tumours of Long- and Short-term Glioblastoma Survivors. J Natl Cancer Inst 2011; 103: 598-601.

67. Donson A, Birks D, Schittone S, et al. Increased Immune Gene Expression and Immune Cell Infiltration in High-Grade Astrocytoma Distinguish Long-Term from Short-Term Survivors. The J Immunol 2012; 189: 1920-7.

68. Geisenberger C, Mock A, Warta R, et al. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica 2015; 130: 419-34.

69. Gieryng A, Pszczolkowska D, Walentynowicz K, Rajan W, Kaminska B. Immune microenvironment of gliomas. Laboratory Investigation 2017; 97: 498-518.

70. Mieczkowski J, Kocyk M, Nauman P, et al. Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget 2015; 6: 33077-90.

Address for correspondence

Bozena Kaminska
Laboratory of Molecular Neurobiology
Nencki Institute of Experimental Biology of the Polish Academy of Sciences
Pasteura 3
02-093 Warsaw, Poland
e-mail: b.kaminska@nencki.gov.pl